We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Antibodies by Design and JPT Peptide Technologies Announce Cooperation Agreement
News

Antibodies by Design and JPT Peptide Technologies Announce Cooperation Agreement

Antibodies by Design and JPT Peptide Technologies Announce Cooperation Agreement
News

Antibodies by Design and JPT Peptide Technologies Announce Cooperation Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Antibodies by Design and JPT Peptide Technologies Announce Cooperation Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Antibodies by Design and JPT Peptide Technologies have announced the start of a co-marketing agreement between the two companies.

Within the scope of this agreement the parties agree to co-market the rapid generation of monoclonal antibodies by Antibodies by Design and the complementary peptide-based services and products from JPT.

Each partner will offer the services of the other to its customers throughout the world-wide market, with exception of Japan.

"We are very glad to have reached an agreement with JPT which bears enormous advantages for both companies, and also for our customers," stated Dieter Lingelbach, Head of the Antibodies by Design division and Senior Vice President of MorphoSys AG.

He adds, "Both companies are absolute specialists in their field and belong to the top addresses for antibody development and innovative peptide-based services in Europe."

"MorphoSys' unique antibody repertoire is the ideal complement to our immunology tools program which includes the peptide array platforms PepSpot™ and PepStar™ plus the novel PepMix™ technology for effective T-lymphocyte stimulation," said Holger Wenschuh, Managing Director of JPT.

He adds, "This co-marketing agreement will allow both companies to address new customers and offer them an even wider package of immunology services."
Advertisement